Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse.
Oliver HoffmannSebastian WormlandAnn-Kathrin BittnerMonika CollenburgPeter A HornRainer KimmigSabine Kasimir-BauerVera RebmannPublished in: Journal of cancer research and clinical oncology (2022)
as an eligibility criterion for PD-1 ICI approaches.